Results 71 to 80 of about 7,838 (234)
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT A 42‐year‐old antibiotic‐naïve man with previous laparoscopic cholecystectomy and poorly controlled type 2 diabetes mellitus (HbA1c 9.7%) presented with Charcot's triad 7 days after a formally documented normal hepatobiliary evaluation (alanine aminotransferase [ALT] 22 U/L; total bilirubin 0.7 mg/dL [12 μmol/L]; common bile duct [CBD] ≤ 5 mm ...
Hatem Mousa Taha, Khaled Hatem Taha
wiley +1 more source
Clinical Pharmacokinetics, 2020 Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control.
J. Leohr +9 more
semanticscholar +1 more source
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli +3 more
wiley +1 more source
Diabetes Technology & Therapeutics, 2020 Background: Ultra rapid lispro (URLi) is a new insulin lispro formulation that has accelerated absorption and improved postprandial glucose control compared with insulin lispro (Humalog®). The compatibility and safety of URLi versus lispro were evaluated
B. Bode +6 more
semanticscholar +1 more source
Diabetes Therapy, 2021 The PRONTO-T1D study evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes mellitus. After 26 weeks of treatment, mealtime and postmeal URLi provided effective and comparable glycemic control in a ...
J. Miura +2 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9423-9432, October 2026.ABSTRACT Aims To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 [500 U/mL]; AT278‐U500) compared with standard concentration insulin aspart (InsAsp [100 U/mL]; InsAsp‐U100) and U500 human regular insulin (HumIns [500 IU/mL]; HumIns‐U500). Materials and Methods This single‐centre, randomised,
Eva Svehlikova +11 more
wiley +1 more source
Revisão da hiperglicemia pós-prandial e a hipoglicemia no controle do diabetes mellitus: o papel da insulina lispro e suas pré-misturas nos picos e vales [PDF]
, 2001 Correction of post-prandial hyperglycemia is increasingly becoming important to patients with diabetes type 1 (DM1) and type 2 (DM2) in order to reduce their risk of morbidity and mortality.
Milech, Adolpho +5 more
core +1 more source
Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report
Diabetology & Metabolic Syndrome, 2011 Introduction Circumscript, progressing lipoatrophy at the insulin injection sites is an unexplained, however rare condition in diabetes mellitus. Case presentation We report a case of severe localised lipoatrophy developing during insulin pump-treatment (
Chantelau Ernst A +3 more
doaj +1 more source
Frontiers in Veterinary Science, 2020 The use of rapid-acting insulin analogs as routes of administration other than IV has never been described for the treatment of dogs with diabetic ketoacidosis (DKA).
Eleonora Malerba +4 more
doaj +1 more source
Birth Defects Research, Volume 118, Issue 9, September 2026.ABSTRACT Background With approximately 50% of pregnancies being unplanned, there is an unintended exposure to potential feto‐toxic drugs that may cause major congenital malformations (MCM). This study aims to compare the predictive performance between traditional pharmacoepidemiologic (PE) and machine learning (ML) models. Methods We conducted a cohort
Gabra Nohmie +7 more
wiley +1 more source